866-997-4948(US-Canada Toll Free)

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 55 Pages

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.

Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary (Hypogonadotropic) Hypogonadism - Overview
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
Merck & Co Inc
Mereo Biopharma Group Plc
Repros Therapeutics Inc
Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
BGS-649 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSS-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
Featured News & Press Releases
Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis
Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
Aug 15, 2016: Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company
Jan 04, 2016: Repros Updates Enclomiphene Program
Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene
Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism
Jun 08, 2015: Repros Announces Date of FDA Advisory Committee Review of NDA
Apr 15, 2015: Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, H1 2017
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H1 2017
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Repros Therapeutics Inc, H1 2017
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H1 2017
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *